Dr. Maya Dimitrova says tumor-infiltrating lymphocyte therapy could expand available melanoma treatments.

The combination of olaparib and bevacizumab represents a new standard of care, Dr. Eva Chalas says.

Dr. Oren Cahlon has been appointed senior vice president and deputy chief clinical officer.

Dr. Elisabeth J. Cohen is enhancing the department’s longstanding commitment to research.

Together, psilocybin and psychotherapy reduced alcohol consumption by 83 percent among heavy drinkers.

Dr. Elaine Shum is leading this trial, which aims to fill an unmet need for targeted therapies.

Joining the Experimental Therapeutics Clinical Trials Network advances cancer clinical trial capabilities.

Adjuvant immunotherapy could help people avoid treatment for metastatic melanoma.

Dr. Catherine S. Diefenbach serves as the principal investigator for numerous lymphoma clinical trials.

Dr. Jeffrey Weber says a person’s microbiome may impact the effectiveness of checkpoint inhibitor therapy.